...
首页> 外文期刊>Journal of Contemporary Brachytherapy >Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results
【24h】

Accelerated partial breast irradiation in a single 18 Gy fraction with high-dose-rate brachytherapy: preliminary results

机译:高剂量率近距离放射疗法在单次18 Gy分数下加速局部乳房照射:初步结果

获取原文
           

摘要

Introduction To evaluate the feasibility of acute and chronic toxicity in patients suitable for accelerated partial breast irradiation (APBI) in a single 18 Gy fraction with multicatheter high-dose-rate (HDR) brachytherapy, as well as cosmetic and oncological outcomes. Material and methods Between September 2014 and March 2016, twenty consecutive patients with low-risk invasive and ductal carcinoma in situ were treated with interstitial multicatheter HDR brachytherapy in a single 18 Gy fraction. Results Median age was 63.5 years (range, 51-79). Acute toxicity was observed in seven patients, while the pain during following days and hematoma were seen in four patients. With a median follow-up of 24 months, late toxicity was found in one patient with fat necrosis g2 and fibrosis g2 in another patient. The overall survival (OS) and locoregional control (LC) was 100%. Disease-free survival (DFS) and distant control was 95%. Good to excellent cosmetic outcomes were noted in 80% of patients and fair in 4 patients (20%). Conclusions This is the first report in the medical literature that focuses on feasibility and acute and chronic toxicity, with a median follow-up of 24 months (range, 20-40). The protocol is viable and convenient. However, a longer follow-up is needed to know chronic toxicity and oncologic outcomes.
机译:简介为了评估在多导管高剂量率(HDR)近距离放疗的单次18 Gy分数下适合于加速部分乳房照射(APBI)的患者的急性和慢性毒性的可行性,以及美容和肿瘤治疗的效果。材料和方法在2014年9月至2016年3月之间,连续20例低危浸润性和导管原位癌患者接受了18Gy分数的间质多导管HDR近距离放射治疗。结果中位年龄为63.5岁(范围51-79)。在7例患者中观察到急性毒性,而在4例患者中观察到随后几天的疼痛和血肿。中位随访期为24个月,在另一例患者中,脂肪坏死g2和纤维化g2的一名患者发现了晚期毒性。总体生存率(OS)和局部控制(LC)为100%。无病生存率(DFS)和远距离控制率为95%。在80%的患者中观察到良好至极好的美容效果,在4例(20%)的患者中表现良好。结论这是医学文献中第一份侧重于可行性以及急性和慢性毒性的报告,中位随访期为24个月(范围20-40)。该协议既可行又方便。但是,需要更长的随访时间来了解慢性毒性和肿瘤学结局。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号